Tomato bredie

KAIST and Checkmate Capital Complete Investment in Bredis Healthcare

Retrieved on: 
Thursday, May 25, 2023

SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”). Bredis is a leading neurodegenerative diagnostics company that has pioneered its patent-protected, digital ELISA technology that is 10,000 times more sensitive than existing blood test technology.

Key Points: 
  • Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea
    SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”).
  • KAIST led the redeemable convertible preferred stock investment and Checkmate was the sole non-Korean investor.
  • As a startup team from KAIST, we believe Bredis will become a promising biomarker-based diagnostics enterprise that grows rapidly through the KAIST startup ecosystem,” commented Henry Chung, CEO of KAIST Ventures.
  • “We are delighted that Bredis is Checkmate’s first direct investment in Korea, sourced through our new international office based in Seoul, and our first collaborative investment with our trusted partner, KAIST,” stated Jay Ryu, Managing Director of Checkmate.